Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
VR

NASDAQ · VRCA

Verrica Pharmaceuticals Inc.

Healthcare · Biotechnology

$4.91

Down-$0.04 (-0.81%)

Updated Sep 12, 2026, 2:37 PM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
79.81M
P/E ratio
-3.07
Dividend yield
0.00%
52-week range
$4.25 – $8.50
Volume
41.89K
Avg. volume
399.36K

Price performance

VRCA price history

1M range · 20 trading sessions · Daily adjusted prices

VRCA closed at $4.91 after 20 trading sessions, down 1.21% for the selected period.

Last close
$4.91
Period change
-1.21%
Period low
$4.68
Period high
$5.69
Daily close
View OHLC price history
VRCA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$4.99$5.03$4.80$4.9141.89K
Sep 10, 2026$5.06$5.25$4.86$4.9556.97K
Sep 9, 2026$5.25$5.40$5.05$5.0647.81K
Sep 8, 2026$5.30$5.4144$5.04$5.26112.2K
Sep 4, 2026$5.28$5.525$5.25$5.3012.2K
Sep 3, 2026$5.48$5.63$5.27$5.3655.39K
Sep 2, 2026$5.32$5.56$5.2837$5.3931.08K
Sep 1, 2026$5.36$5.56$5.22$5.2443.49K
Aug 31, 2026$5.70$5.8308$5.295$5.46106.42K
Aug 28, 2026$5.12$5.86$5.00$5.69351.92K
Aug 27, 2026$5.01$5.65$4.90$5.07533.71K
Aug 26, 2026$4.86$5.055$4.84$4.9127.66K
Aug 25, 2026$4.90$4.99$4.75$4.9454.91K
Aug 24, 2026$4.81$4.9499$4.61$4.8767.96K
Aug 21, 2026$4.90$4.99$4.64$4.8278.82K
Aug 20, 2026$4.99$5.1811$4.83$4.86138.48K
Aug 19, 2026$5.22$5.22$4.77$4.99169.81K
Aug 18, 2026$4.90$5.00$4.68$4.6850.3K
Aug 17, 2026$5.00$5.15$4.7651$4.89179.72K
Aug 14, 2026$4.89$5.0983$4.78$4.9759.64K

Latest VRCA news

The latest Smart Investors Daily articles mentioning VRCA.

Stock researchCompany · Overview

VRCA research

Overview

Company profile and research snapshot.

Company profile

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
12
VRCA recent ratings
DateFirmRatingTarget
Dec 18, 2025Brookline CapitalBuy—
May 14, 2025NeedhamHold—
Apr 9, 2025NeedhamHold—
Apr 8, 2025HC Wainwright & Co.Neutral—
Mar 12, 2025NeedhamHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 28th Annual Global Investment Conference. H.C. Wainwright 28th Annual Global Investment ConferenceEvent d

Yahoo · Aug 27, 2026

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 – WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological disea

Yahoo · Aug 7, 2026

Verrica Pharmaceuticals Q2 Earnings Call Highlights

Verrica Pharmaceuticals (NASDAQ:VRCA) reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash runway into 2028. C

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By